ANALYSIS OF HEMATOLOGIC, HEPATIC AND PANCREATIC TOXICITY DURING NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER

Purpose. We analyzed the frequency and severity of hematologic, hepatic and pancreatic toxicity during and after completion of neoadjuvant chemoradiotherapy in patients with gastric cancer.

Material and methods. Phase II clinical trial was conducted to  evaluate the efficacy of the combined modality treatment including neoadjuvant chemoradiotherapy followed by D2  gastrectomy for patients with locally advanced gastric cancer. The  main inclusion criteria were: histologically verified gastric cancer,  cT3-4N0, cT2-4N1-3; M0. Before starting neoadjuvant therapy, all  patients underwent thoracic and abdominal CT and laparoscopy to  exclude peritoneal carcinomatosis. A total dose of radiation therapy  was 45 Gy (1 + 1.5 Gy/fraction/day with a 4–5 hour interval)  concurrently with the modified CAPOX chemotherapy regimen.  Gastrectomy or subtotal resection of the stomach was planned 4-6  weeks after the completion of chemoradiotherapy. The toxicity  assessment of neoadjuvant chemoradiotherapy was performed using the NCI CTC scale, version 3.0. The assessment of hematological, hepatic and pancreatic toxicities was done.

Results. Among the toxicity during and after completion of  neoadjuvant chemoradiotherapy, thrombocytopenia, neutropenia and leukopenia (grade 1–2) were the most common, requiring no  additional symptomatic therapy. Radiation therapy was completed in  45 (98 %) patients. Chemotherapy was completed in 42 (91 %)  patients. The median time between the completion of  chemoradiotherapy and surgery was 44 days. Surgery following  chemoradiotherapy was performed in 100 % of patients, including R0 resection in 93 % of patients.

Conclusion. Preoperative chemoradiotherapy was well tolerated by  patients, could be completed in most cases and did not prevent  subsequent surgical treatment.

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136 (5): E35986. doi: 10.1002/ijc.29210.

2. Kaprin A.D., Starinskij V.V., Petrova G.V. Malignant neoplasms in Russia in 2016 (morbidity and mortality). Moscow, 2017. 30. [in Russian]

3. Takebayashi K., Murata S., Yamamoto H., Ishida M., Yamaguchi T., Kojima M, Shimizu T., Shiomi H., Sonoda H., Naka S., Mekata E., Okabe H., Tani T. Surgery- induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer. Ann Surg Oncol. 2014; Jun 21 (6): 1991–97. doi: 10.1245/s10434-014-3525-9

4. Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., Haller D.G., Ajani J.A., Gunderson L.L., Jessup J.M., Martenson J.A. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6; 345 (10): 725–30.

5. Cunningham D., Allum W. H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S., Chua Y.J., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355 (1): 11–20. doi: 10.1056/NEJMoa055531.

6. Ronellenfitsch U., Schwarzbach M., Hofheinz R., Kienle P., Kieser M., Slanger T.E., Burmeister B., Kelsen D., Niedzwiecki D., Schuhmacher C., Urba S., van de Velde C., Walsh T.N., Ychou M., Jensen K. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta- analysis combining individual patient and aggregate data. Eur J Cancer. 2013 Oct; 49 (15): 3149–58. doi: 10.1016/j.ejca.2013.05.029.

7. Blank S., Stange A., Sisic L., Roth W., Grenacher L., Sterzing F., Burian M., Jäger D., Büchler M., Ott K. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg. 2013 Feb; 398 (2): 211–20. doi: 10.1007/s00423-012-1034-5.

8. Aoyama T., Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017 Nov; 47 (11): 1295–302. doi: 10.1007/s00595-017-1493-y.

9. Shapiro J., van Lanschot J.J., Hulshof M.C., van Hagen P., van Berge Henegouwen M.I., Wijnhoven B.P., van Laarhoven H.W., Nieuwenhuijzen G.A., Hospers G.A., Bonenkamp J.J., Cuesta M.A., Blaisse R.J., Busch O.R., Ten Kate F.J., Creemers G.J., Punt C.J., Plukker J.T., Verheul H.M., Bilgen E.J., van Dekken H., van der Sangen M.J., Rozema T., Biermann K., Beukema J.C., Piet A.H., van Rij C.M., Reinders J.G., Tilanus H.W., Steyerberg E.W., van der Gaast A.; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep; 16 (9): 1090–98. doi: 10.1016/S1470-2045(15)00040-6.

10. Berdov B.A, Scoropad V.Yu, Titova L.N, Evdikimov L.V. Method of combined treatment of locally advanced stomach cancer. Patent № 2478407 Russia. № 2011136818/14; 10.04.2013. [in Russian]

11. Stahl M., Walz M.K., Stuschke M., Lehmann N., Meyer H.J., Riera-Knorrenschild J., Langer P., Engenhart-Cabillic R., Bitzer M., Königsrainer A., Budach W.., Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009 Feb 20; 27 (6): 851–6. doi: 10.1200/JCO.2008.17.0506.

12. Wydmański J., Suwinski R., Poltorak S., Maka B., Miszczyk L., Wolny E., Bielaczyc G., Zajusz A. The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study. Radiother Oncol. 2007 Feb; 82 (2): 132–6

13. Samel S., Hofheinz R., Hundt A., Sturm J., Knoll M.R., Wenz F., Queisser W., Post S. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction. Onkologie. 2001 Jun; 24 (3): 278–82.

14. Chakravarty T., Crane C.H., Ajani J.A., Mansfield P.F., Briere T.M., Beddar A.S., Mok H., Reed V.K., Krishnan S., Delclos M.E., Das P. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 1; 83 (2): 581–6. doi: 10.1016/j.ijrobp.2011.07.035.

15. Trip A.K., Poppema B.J., van Berge Henegouwen M.I., Siemerink E., Beukema J.C., Verheij M., Plukker J.T., Richel D.J., Hulshof M.C., van Sandick J.W., Cats A., Jansen E.P., Hospers G.A. Preoperative chemoradiotherapy in locally advanced gastric

16. cancer, a phase I/II feasibility and efficacy study. Radiother Oncol. 2014 Aug; 112 (2): 284–8. doi: 10.1016/j.radonc.2014.05.003.

17. Zolotkov A.G., Mardynskij Ju.S., Val’kov M.Ju., Gulidov I.A., Petelin G.I., Titova L.N., Ragulin Ju.A., Krasil’nikov A.V., Jefendiev V.A. Accelerated radiotherapy for inoperable gastric cancer. Siberian Journal of Oncology. 2011; 4: 11–14. [in Russian]

18. Kaprin A.D., Galkin V.N., Zhavoronkov L.P., Ivanov V.K., Ivanov S.A., Romanco Yu.S. Synthesis of fundamental and applied research is the basis for ensuring a high level of scientific results and their introduction into medical practice. Radiation and risk. 2017; 26 (2): 26–40. [in Russian]